AB99757

Mouse monoclonal [JDC-10] Anti-Human IgG Fc

Name: Mouse Anti-Human IgG Fc secondary antibody (ab99757) | Abcam
Brand: Abcam Limited
SKU: AB99757

Be the first to review this product! Submit a review

(12 Publications)

Mouse monoclonal Anti-Human IgG Fc is an unconjugated secondary antibody that is suitable for Western blot, IHC, ICC/IF, ELISA, ICC and more.

- Reacts with the Fc portion of the heavy chain of all subclasses of Human IgG

View Alternative Names

Immunoglobulin heavy constant gamma 1, Ig gamma-1 chain C region, Ig gamma-1 chain C region EU, Ig gamma-1 chain C region KOL, Ig gamma-1 chain C region NIE, IGHG1

Alkaline Phosphatase

Mouse monoclonal [JDC-10] Anti-Human IgG Fc (Alkaline Phosphatase)
HRP

Mouse monoclonal [JDC-10] Anti-Human IgG Fc (HRP)
578 PE

Mouse monoclonal [JDC-10] Anti-Human IgG Fc (PE)

Key facts

Host species

Mouse

Target species

Human

Target isotype

IgG

Target specificity

Fc region

Minimal cross-reactivity

Pre-adsorbed

Applications

ICC, WB, IHC-Fr, Dot, ELISA, ICC/IF

applications

Clonality

Monoclonal

Clone number

JDC-10

Isotype

IgG1

Light chain type

kappa

Immunogen

Native Full Length Protein corresponding to Human IGHG1.

P01857

Specificity

ab99757 reacts with the Fc portion of the heavy chain of all subclasses of Human IgG as demonstrated by ELISA; may also react with IgG from other species.

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "ICC/IF": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"1 µg for 10^6 Cells", "notes":"for indirect immunofluorescent staining of IgG+ Human B lymphocytes." }, "Dot": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"" }, "ELISA": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"" }, "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"" }, "ICC": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"" }, "IHC-Fr": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"" } } }

style

left-column

Product details

This antibody reacts with the Fc region of Human IgG.

When it comes to advancing your immunohistochemistry (IHC) research, Abcam offers comprehensive suite of IHC kits and secondary antibodies, designed to deliver precise and reliable results.

The immunogen is purified human IgG1 myeloma protein.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

style

left-column

Properties and storage information

Form

Liquid

Purification technique

Affinity purification Protein G

Storage buffer

pH: 8.2 Constituents: 100% Borate buffered saline

Shipped at conditions

Blue Ice

Appropriate short-term storage duration

1-2 weeks

Appropriate short-term storage conditions

+4°C

Appropriate long-term storage conditions

-20°C

Aliquoting information

Upon delivery aliquot

Storage information

Avoid freeze / thaw cycle

style

left-column

style

left-column

style

left-column

Product protocols

Visit the General protocols
Visit the Troubleshooting

style

left-column

Target data

Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed : 20176268, PubMed : 22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed : 17576170, PubMed : 20176268). Mediates IgG effector functions on monocytes triggering ADCC of virus-infected cells.

See full target information IGHG1

Additional targets

IGHG3,IGHG2,IGHG4

style

left-column

Publications (12)

Recent publications for all applications. Explore the full list and refine your search

Materials today. Bio 34:102233 PubMed40917514

2025

Engineered biomimetic vesicles induce cuproptosis and disrupt efferocytosis for metastatic adenoid cystic carcinoma immunotherapy.

Applications

Unspecified application

Species

Unspecified reactive species

Mingyang Li,Wenjing Dong,Yuhan Cui,Jingwen Li,Chenyu Yang,Dongsheng Zhang,Xiao Fu

Acta neuropathologica 149:55 PubMed40455292

2025

Anti-pyroglutamate-3 Aβ immunotherapy engages microglia and inhibits amyloid accumulation in transgenic mouse models of Aβ amyloidosis.

Applications

Unspecified application

Species

Unspecified reactive species

Fan Liao,Maria Calvo-Rodriguez,Meha Chhaya,Julian P Sefrin,Erik I Charych,Mario Mezler,Diana Clausznitzer,Emily J McGlame,Karen Zhao,Allison Rodgers,Yang Cao,Philipp F Secker,Laura Fernandez Garcia-Agudo,Lili Huang,Corinna Klein,Tammy Dellovade,Eric Karran

Frontiers in pharmacology 15:1464852 PubMed39744125

2025

Transcription factor MEF2D regulates aberrant expression of ACSL3 and enhances sorafenib resistance by inhibiting ferroptosis in HCC.

Applications

Unspecified application

Species

Unspecified reactive species

Xue Li,Shimin Chen,Yuanyuan Shi,Yuanjing Wang,Xuanzhe Wang,Qian Lin,Chao Wu,Wenshuo Fang,Peng Sun,Leina Ma

Molecular therapy : the journal of the American Society of Gene Therapy 32:3729-3742 PubMed39228125

2024

Reduction of circulating IgE and allergens by a pH-sensitive antibody with enhanced FcγRIIb binding.

Applications

Unspecified application

Species

Unspecified reactive species

Na Li,Nanxin Gong,Baoxin Duan,Yongyan Zhang,Yi Jian,Yanqin Xu,Jinming Liu,Xiaoqian Wang,Xiaoqi Zhang,Mingjuan Du,Feilong Zhou,Jiliang Zhao,Xiangchen Guan,Xiangda Peng,Sheng Wang,Hongkai Zhang,Xin Li

Journal of orthopaedic translation 45:211-225 PubMed38586591

2024

IRF1 governs the expression of SMARCC1 via the GCN5-SETD2 axis and actively engages in the advancement of osteoarthritis.

Applications

Unspecified application

Species

Unspecified reactive species

Dong Wang,Yujun Zhang,Liangping Zhang,Du He,Lan Zhao,Zhimin Miao,Wei Cheng,Chengyue Zhu,Li Zhu,Wei Zhang,Hongting Jin,Hang Zhu,Hao Pan

Experimental and therapeutic medicine 23:277 PubMed35317443

2022

Monomeric C-reactive protein level is associated with osteoarthritis.

Applications

Unspecified application

Species

Unspecified reactive species

Yulin Liang,Ke Xu,Wenguang Liu,Xiaoling Liu,Ping Yuan,Peng Xu,Haiyun Li

International journal of biological macromolecules 195:609-619 PubMed34871658

2021

Precise location of two novel linear epitopes on the receptor-binding domain surface of MERS-CoV spike protein recognized by two different monoclonal antibodies.

Applications

Unspecified application

Species

Unspecified reactive species

Pan Wang,Peiyang Ding,Qiang Wei,Hongliang Liu,Yunchao Liu,Qingmei Li,Yunrui Xing,Ge Li,Enmin Zhou,Gaiping Zhang

Bioengineered 12:11138-11155 PubMed34783292

2021

DNA methyltransferase 3 beta mediates the methylation of the microRNA-34a promoter and enhances chondrocyte viability in osteoarthritis.

Applications

Unspecified application

Species

Unspecified reactive species

Shouliang Xiong,Yong Zhao,Tiantong Xu

Biochemical and biophysical research communications 571:152-158 PubMed34325131

2021

A non-RBM targeted RBD specific antibody neutralizes SARS-CoV-2 inducing S1 shedding.

Applications

Unspecified application

Species

Unspecified reactive species

Yingyi Long,Shuyi Song,Feiyang Luo,Xiaojian Han,Chao Hu,Yingming Wang,Shenglong Li,Wang Wang,Huajun Zhang,Bo Zhang,Tingting Li,Aishun Jin

Cancer research 81:3402-3414 PubMed33687950

2021

Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors.

Applications

Unspecified application

Species

Unspecified reactive species

Darren C Phillips,Fritz G Buchanan,Dong Cheng,Larry R Solomon,Yu Xiao,John Xue,Stephen K Tahir,Morey L Smith,Haichao Zhang,Deborah Widomski,Vivek C Abraham,Nan Xu,Zhihong Liu,Li Zhou,Enrico DiGiammarino,Xin Lu,Nandini Rudra-Ganguly,Bruce Trela,Susan E Morgan-Lappe

View all publications

style

left-column

style

left-column

style

right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.

For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Mouse monoclonal [JDC-10] Anti-Human IgG Fc

Related conjugates and formulations (3)

Key facts

Host species

Target species

Target isotype

Target specificity

Minimal cross-reactivity

Pre-adsorbed

Applications

Clonality

Clone number

Isotype

Light chain type

Immunogen

Specificity

Reactivity data

Product details

Properties and storage information

Form

Purification technique

Storage buffer

Shipped at conditions

Appropriate short-term storage duration

Appropriate short-term storage conditions

Appropriate long-term storage conditions

Aliquoting information

Storage information

Product protocols

Target data

Additional targets

Publications (12)

Complementary Products

Secondary Antibodies

Reagents, Controls & Accessories

Primary Antibodies

Secondary Antibodies

Primary Antibodies

Primary Antibodies

Product promise